Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1485849
This article is part of the Research Topic Advancements in Immune Heterogeneity in Inflammatory Diseases and Cancer: New Targets, Mechanisms, and Strategies View all 3 articles

Combined systemic immune-inflammatory index and prognostic nutritional index predicts the efficacy and prognosis of ES-SCLC patients receiving PD-L1 inhibitors combined with first-line chemotherapy

Provisionally accepted
Yi Ge Yi Ge 1*Xiaoyu Liu Xiaoyu Liu 2Yishi Xu Yishi Xu 1Yanwei Su Yanwei Su 1Yixin Li Yixin Li 1,3Liping Wang Liping Wang 1
  • 1 First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
  • 2 Luohe Central Hospital, Luohe, China
  • 3 Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

The final, formatted version of the article will be published soon.

    Background: There is a strong association between inflammation and the formation, progression, and metastasis of malignant tumors, according to earlier studies. Some composite inflammationnutritional indicators, such as the systemic immune-inflammation index (SII) and the prognostic nutritional index (PNI), have a certain predictive effect on the prognosis of patients with small cell lung cancer (SCLC). However, the relationship between these indicators and the efficacy of immunotherapy in SCLC patients is still not well understood. Therefore, the purpose of this study was to explore how the pre-treatment SII-PNI score can predict the tumor response and prognosis of extensive-stage SCLC patients treated with PD-L1 inhibitors and first-line chemotherapy.Methods: This research conducted a retrospective review of 70 ES-SCLC patients from December 2019 to January 2023. According to the SII-PNI score, all patients were categorized into three groups. Overall survival (OS) was assessed by implementing the Kaplan Meier and Cox regression models. In addition, we devised a nomogram and scrutinized its accuracy in prediction through receiver operating characteristic (ROC) curve analysis and visualized it by calibration plots. Subsequently, a risk classification system was established.Results: Patients with higher SII-PNI scores exhibited notably poorer survival outcomes compared to their counterpart with low SII-PNI score (p=0.008), as well as poorer short-term curative effects (p=0.004). The results of the multivariate analysis revealed that the SII-PNI score (p=0.036) had an independent association with a less favorable OS. The nomogram has been demonstrated to be a reliable prognostic tool for ES-SCLC patients. A notable difference was identified between the two different levels of risk.The baseline SII-PNI score can serve as a reliable prognostic indicator for ES-SCLC patients receiving immunotherapy. Higher SII-PNI scores imply a worse prognosis.

    Keywords: Small Cell Lung Cancer, PD-L1 inhibitors, systemic immune-inflammation index, Prognostic nutritional index, survival. Article types: Original Research small cell lung cancer, Survival

    Received: 25 Aug 2024; Accepted: 12 Nov 2024.

    Copyright: © 2024 Ge, Liu, Xu, Su, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yi Ge, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.